Tevogen Bio Holdings shares rise 10.26% premarket as analysts expect breakeven by 2027.

Tevogen Bio Holdings (NASDAQ:TVGN) rose 10.26% in premarket trading amid analyst-driven optimism about its path to breakeven. Recent analysis from Simply Wall St highlighted expectations for the company to turn a $259 million profit in 2027, following a projected final loss in 2026, implying a 52% annual growth rate. While the firm currently reports a $31 million trailing-twelve-month loss and negative equity, the anticipated turnaround—despite being optimistic—signals potential investor confidence in its long-term profitability. The biotech sector’s typical volatile cash flows and high-growth trajectories further contextualize the market’s positive reaction to these forward-looking projections.